Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
Matthew B. Dong, Guangchuan Wang, Ryan D. Chow, et al.
Cell (2019) Vol. 178, Iss. 5, pp. 1189-1204.e23
Open Access | Times Cited: 254

Showing 1-25 of 254 citing articles:

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Karthik Dhatchinamoorthy, Jeff D. Colbert, Kenneth L. Rock
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 698
CD8+ T cell differentiation and dysfunction in cancer
Mary Philip, Andrea Schietinger
Nature reviews. Immunology (2021) Vol. 22, Iss. 4, pp. 209-223
Open Access | Times Cited: 695
Ferroptosis in cancer and cancer immunotherapy
Lei Zhao, Xiaoxue Zhou, Feng Xie, et al.
Cancer Communications (2022) Vol. 42, Iss. 2, pp. 88-116
Open Access | Times Cited: 428
High-content CRISPR screening
Christoph Bock, Paul Datlinger, Florence M. Chardon, et al.
Nature Reviews Methods Primers (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 375
CAR immune cells: design principles, resistance and the next generation
Louai Labanieh, Crystal L. Mackall
Nature (2023) Vol. 614, Iss. 7949, pp. 635-648
Closed Access | Times Cited: 347
CRISPR in cancer biology and therapy
Alyna Katti, Bianca J. Diaz, Christina M. Caragine, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 5, pp. 259-279
Open Access | Times Cited: 296
An NK-like CAR T cell transition in CAR T cell dysfunction
Charly R. Good, M. Ángela Aznar, Shunichiro Kuramitsu, et al.
Cell (2021) Vol. 184, Iss. 25, pp. 6081-6100.e26
Open Access | Times Cited: 271
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence
Julia A. Belk, Winnie Yao, Nghi Ly, et al.
Cancer Cell (2022) Vol. 40, Iss. 7, pp. 768-786.e7
Open Access | Times Cited: 219
High-content CRISPR screening
Christoph Bock, Paul Datlinger, Florence M. Chardon, et al.
Nature Reviews Methods Primers (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 207
Promises and challenges of adoptive T-cell therapies for solid tumours
Matteo Morotti, Ashwag Albukhari, Abdulkhaliq Alsaadi, et al.
British Journal of Cancer (2021) Vol. 124, Iss. 11, pp. 1759-1776
Open Access | Times Cited: 201
CRISPR activation and interference screens decode stimulation responses in primary human T cells
Ralf Schmidt, Zachary Steinhart, Madeline Layeghi, et al.
Science (2022) Vol. 375, Iss. 6580
Open Access | Times Cited: 191
Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 186
A new era in functional genomics screens
Laralynne Przybyla, Luke A. Gilbert
Nature Reviews Genetics (2021) Vol. 23, Iss. 2, pp. 89-103
Closed Access | Times Cited: 183
Epigenetic regulation of T cell exhaustion
Julia A. Belk, Bence Dániel, Ansuman T. Satpathy
Nature Immunology (2022) Vol. 23, Iss. 6, pp. 848-860
Open Access | Times Cited: 183
An expanded universe of cancer targets
William C. Hahn, Joel S. Bader, Theodore P. Braun, et al.
Cell (2021) Vol. 184, Iss. 5, pp. 1142-1155
Open Access | Times Cited: 182
Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
Theodore L. Roth, P. Jonathan Li, Franziska Blaeschke, et al.
Cell (2020) Vol. 181, Iss. 3, pp. 728-744.e21
Open Access | Times Cited: 161
In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer
Zeyu Chen, Eri Arai, Omar Khan, et al.
Cell (2021) Vol. 184, Iss. 5, pp. 1262-1280.e22
Open Access | Times Cited: 158
Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
Shuhang Wang, Jingwei Sun, Kun Chen, et al.
BMC Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 154
Synthetic Lethality in Cancer Therapeutics: The Next Generation
Jeremy Setton, Michael Zinda, Nadeem Riaz, et al.
Cancer Discovery (2021) Vol. 11, Iss. 7, pp. 1626-1635
Open Access | Times Cited: 142
A genome-scale screen for synthetic drivers of T cell proliferation
Mateusz Legut, Zoran Gajic, Maria Guarino, et al.
Nature (2022) Vol. 603, Iss. 7902, pp. 728-735
Open Access | Times Cited: 138
RASA2 ablation in T cells boosts antigen sensitivity and long-term function
Julia Carnevale, Eric Shifrut, Nupura Kale, et al.
Nature (2022) Vol. 609, Iss. 7925, pp. 174-182
Open Access | Times Cited: 130
A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy
Lupeng Ye, Jonathan J. Park, Lei Peng, et al.
Cell Metabolism (2022) Vol. 34, Iss. 4, pp. 595-614.e14
Open Access | Times Cited: 128
Next-Generation CAR T-cell Therapies
Regina M. Young, Nils W. Engel, Uğur Uslu, et al.
Cancer Discovery (2022) Vol. 12, Iss. 7, pp. 1625-1633
Open Access | Times Cited: 128
The future of engineered immune cell therapies
Darrell J. Irvine, Marcela V. Maus, David Mooney, et al.
Science (2022) Vol. 378, Iss. 6622, pp. 853-858
Open Access | Times Cited: 122
Genetic engineering of T cells for immunotherapy
Gavin I. Ellis, Neil C. Sheppard, James L. Riley
Nature Reviews Genetics (2021) Vol. 22, Iss. 7, pp. 427-447
Open Access | Times Cited: 110
Page 1 - Next Page

Scroll to top